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Identity 
Other names: BRG1; BRG-1; BAF190; FLJ39786; 
hSNF2b; NM_003072; SNF2-beta; SNF2B; 
SNF2L4; SNF2LB; SWI2 







Relative size of the 33 coding exons of SMARCA4. The entire 
exon 1 is UTR (untranslated region). Exon numeration 
corresponds to the prevalent transcript (matching the EST 
EU430759). 
Description 
The SMARCA4 is also known as BRG1 (hSWI/SNF 
brahma-related gene). It spans a total genomic size of 
101347 bp and it is composed of 33 coding exons of 
varying lengths and 1 non-coding exon (exon 1). 
Transcription 
The human SMARCA4 transcript has approxi-mately 
5500 bp and contains an open reading frame of 4845 
bp, predicting a protein of 1614 amino acid residues. 
There are different transcripts arising from two  
alternative splicing sites within intron 28 and exon 30, 
which predict the translation of four different BRG1 
protein isoforms. In addition, between exon 26 and 27 
and exon 29 and 30 there are two additional exons that 
may constitute tissue specific transcripts. 
Protein 
Description 
SMARCA4 has a molecular mass of 181349 Da. 
SMARCA4 is the catalytic subunit of the chromatin-
remodelling complex SWI-SNF and influences 
transcriptional regulation by disrupting histone-DNA 
contacts in an ATP-dependent manner. In addition to 
an ATPase, the SWI/SNF complex is composed of a 





SMARCA4 localizes in the nucleus. 
Function 
The SMARCA4 harbours the ATPase activity required 
for the chromatin remodelling activity of the SWI/SNF 
complex. This complex uses the energy of ATP 
hydrolysis to modify the interactions among histones 
leading to modifica-tions of the chromatin structure and 
to the regulation of gene expression.  
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SMARCA4 conserved domains. Proline rich region, containing more than 25% of proline residues in the aminoacid sequence. HSA and 
BRK domains, containing motifs that may predict binding to DNA. ATPase/helicase domain, contains motifs present in the DEAD 
helicases superfamily, a diverse family of proteins involved in ATP-dependent RNA or DNA unwinding. Bromodomain, 110 aminoacid 
domain, found in many chromatin associated proteins. Bromodomains can interact specifically with acetylated lysine. 
 
The SWI/SNF complex plays a role in differentiation, 
develop-ment and cell cycle control. SMARCA4 binds 
to or it is related to important tumor suppressor 
proteins, including BRCA2, LKB1, RB and FANCA. 
Moreover, the SWI/SNF complex has been shown to 
modulate the transcriptional activity of steroid 
receptors (e.g. glucocorticoids receptors, retinoic acid 
receptors, androgen and estrogen receptors), CMYC 
and RB. SMARCA4 acts as a tumor suppressor 
because: 
i) it induces cell-growth arrest after ectopic expression 
in deficient tumor cells, 
ii) SMARCA4-heterozygous mice have an increased 
predisposition to tumor development and, 
iii) it is biallelically inactivated by homozygous 
deletions or combinations of deletions and mutations in 
several types of tumors, specially in lung cancer. 
Homology 
The mammalian SWI/SNF complex contains either 
SMARCA4 or SMARCA2 as its central ATPase 
subunit. Both ATPases share 80% homology in their 
aminoacid sequence. However, differences in 
expression patterns and in the phenotypes of Brm and 
Brg1 knockout mice suggest specific biological roles 
between both ATPases.  
SMARCA2 and SMARCA4 are orthologous to the 
snf2/swi2 gene from S. cerevisiae and to the "brahma" 
(brm) gene from Drosophila. These encode proteins 
that are highly conserved along evolution, especially in 
the ATPase/helicase domain. Actually, SMARCA2 is 





SMARCA4 somatic mutations have been identified in 
some cancer cell lines including those from the lung, 
prostate, breast, pancreas and colon. While somatic 
mutations have been detected in a small subset of lung 
primary tumors, about one third of the lung cancer cell 
lines of the non-small cell lung cancer type harbour 
inactivating SMARCA4 somatic mutations. All 
mutations are homozygous and most of them predict 
truncated proteins. The type of mutations commonly 
observed include nonsense, indels and large deletions. 
Although less frequently, missense mutations have also 
been reported. Four of the aminoacid substitutions  
found in human lung and colorectal cancer, the 
p.W764R, p.G1160R, p.L1163P and p.S1176C 
represent changes in highly conserved residues within 
the ATPase/helicase domain. In vitro generated muta-
tions of some highly conserved aminoacid within this 
motif lead to a seriously diminished catalytic activity of 
SMARCA4. SMARCA4 germ-line mu-tations have not 
been reported so far. 
Prognosis 
The lost of either SMARCA4 or SMARCA2, detected 
by immunostaining, predicts decreased survival in 
some cancer patients. 
To be noted 
Note 
SMARCA4 is somatically mutated in a significant 
proportion of tumors, in particular lung cancer. Thus, 
SMARCA4 is a bona fide tumor suppressor gene and is 
clearly implicated in cancer develop-ment. 
SMARCB1, encoding another subunit of the SWI/SNF 
complex, is subject to bi-allelic muta-tions (germinal 
and somatic) in rhabdoid tumours, a very aggressive 
form of paediatric cancers. 
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